Literature DB >> 22584777

Cardiac failure 30 years after treatment containing anthracycline for childhood acute lymphoblastic leukemia.

John M Goldberg1, Rebecca E Scully, Stephen E Sallan, Steven E Lipshultz.   

Abstract

In 1977, a 5-year-old girl diagnosed with acute lymphoblastic leukemia was treated on Dana-Farber Cancer Institute Childhood Acute Lymphoblastic Leukemia Protocol 77-01, receiving a cumulative doxorubicin dose of 465 mg/m(2), cranial radiation, and other drugs. After being in continuous complete remission for 34 months, she developed heart failure and was treated with digoxin and furosemide. At 16 years of age, she was diagnosed and treated for dilated cardiomyopathy. Over the years, she continued to have bouts of heart failure, which became less responsive to treatment. At 36 years of age, she received a heart transplant. Six months later, she stopped taking her medications and suffered a sudden cardiac death.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22584777      PMCID: PMC3380184          DOI: 10.1097/MPH.0b013e3182532078

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  40 in total

1.  Characteristics and determinants of adiposity in pediatric cancer survivors.

Authors:  Tracie L Miller; Stuart R Lipsitz; Gabriela Lopez-Mitnik; Andrea S Hinkle; Louis S Constine; M Jacob Adams; Carol French; Cynthia Proukou; Amy Rovitelli; Steven E Lipshultz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

2.  Heart failure in childhood cancer survivors.

Authors:  Steven E Lipshultz
Journal:  Nat Clin Pract Oncol       Date:  2007-04-24

3.  Long term survival after heart transplantation for doxorubicin induced cardiomyopathy.

Authors:  M Aricò; E Pedroni; L Nespoli; M Viganò; F Porta; G R Burgio
Journal:  Arch Dis Child       Date:  1991-08       Impact factor: 3.791

4.  Pediatric heart transplantation for doxorubicin-induced cardiomyopathy.

Authors:  R P McManus; D P O'Hair
Journal:  J Heart Lung Transplant       Date:  1992 Mar-Apr       Impact factor: 10.247

5.  Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer.

Authors:  Steven E Lipshultz; Stuart R Lipsitz; Stephen E Sallan; Valeriano C Simbre; Seema L Shaikh; Suzanne M Mone; Richard D Gelber; Steven D Colan
Journal:  J Clin Oncol       Date:  2002-12-01       Impact factor: 44.544

6.  Phase I study of liposomal annamycin.

Authors:  D J Booser; R Perez-Soler; P Cossum; L Esparza-Guerra; Q P Wu; Y Zou; W Priebe; G N Hortobagyi
Journal:  Cancer Chemother Pharmacol       Date:  2000       Impact factor: 3.333

7.  The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.

Authors:  Steven E Lipshultz; Nader Rifai; Virginia M Dalton; Donna E Levy; Lewis B Silverman; Stuart R Lipsitz; Steven D Colan; Barbara L Asselin; Ronald D Barr; Luis A Clavell; Craig A Hurwitz; Albert Moghrabi; Yvan Samson; Marshall A Schorin; Richard D Gelber; Stephen E Sallan
Journal:  N Engl J Med       Date:  2004-07-08       Impact factor: 91.245

8.  Pediatric heart transplantation for anthracycline cardiomyopathy: cancer recurrence is rare.

Authors:  Kendra M Ward; Helen Binns; Clifford Chin; Steve A Webber; Charles E Canter; Elfriede Pahl
Journal:  J Heart Lung Transplant       Date:  2004-09       Impact factor: 10.247

Review 9.  Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management.

Authors:  Elly Barry; Jorge A Alvarez; Rebecca E Scully; Tracie L Miller; Steven E Lipshultz
Journal:  Expert Opin Pharmacother       Date:  2007-06       Impact factor: 3.889

10.  Psychological outcomes in long-term survivors of childhood leukemia, Hodgkin's disease, and non-Hodgkin's lymphoma: a report from the Childhood Cancer Survivor Study.

Authors:  Brad J Zebrack; Lonnie K Zeltzer; John Whitton; Ann C Mertens; Lorrie Odom; Roger Berkow; Leslie L Robison
Journal:  Pediatrics       Date:  2002-07       Impact factor: 9.703

View more
  4 in total

1.  Why multidisciplinary clinics should be the standard for treating chronic kidney disease.

Authors:  Guido Filler; Steven E Lipshultz
Journal:  Pediatr Nephrol       Date:  2012-07-04       Impact factor: 3.714

Review 2.  Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients.

Authors:  Sibo Tian; Kim M Hirshfield; Salma K Jabbour; Deborah Toppmeyer; Bruce G Haffty; Atif J Khan; Sharad Goyal
Journal:  Front Oncol       Date:  2014-10-09       Impact factor: 6.244

Review 3.  Anti-cancer Therapy Leads to Increased Cardiovascular Susceptibility to COVID-19.

Authors:  Caroline Lozahic; Helen Maddock; Hardip Sandhu
Journal:  Front Cardiovasc Med       Date:  2021-04-23

Review 4.  The Utility of Cardiac Reserve for the Early Detection of Cancer Treatment-Related Cardiac Dysfunction: A Comprehensive Overview.

Authors:  Stephen Foulkes; Guido Claessen; Erin J Howden; Robin M Daly; Steve F Fraser; Andre La Gerche
Journal:  Front Cardiovasc Med       Date:  2020-03-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.